更昔洛韦和缬更昔洛韦在先天性巨细胞病毒感染婴儿中的应用：来自美国多中心电子健康记录数据集的数据。
Ganciclovir and Valganciclovir Use Among Infants With Congenital Cytomegalovirus: Data From a Multicenter Electronic Health Record Dataset in the United States.
机构信息
Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
出版信息
J Pediatric Infect Dis Soc. 2022 Aug 30;11(8):379-382. doi: 10.1093/jpids/piac034.
Among 342 US infants with congenital cytomegalovirus treated with antivirals, 114 (33%) received ganciclovir (with or without valganciclovir) and 228 (67%) received valganciclovir only, for a median of 8 and 171 days, starting at a median of 15 and 45 days of life, respectively, with neutropenia diagnosed in 25% and 17%.
在 342 名接受抗病毒药物治疗的先天性巨细胞病毒感染美国婴儿中，114 名（33%）接受更昔洛韦（联合或不联合缬更昔洛韦）治疗，228 名（67%）接受缬更昔洛韦治疗，中位数疗程分别为 8 天和 171 天，起始治疗中位时间分别为出生后 15 天和 45 天，分别有 25%和 17%的患儿诊断为中性粒细胞减少症。
Zotero 插件